In the past 10 years, the rheumatology community has seen an explosion in the number of new therapies licensed for use across the rheumatic diseases, many with outstanding clinical success. Here, the drugs and strategies that constitute landmarks in the management of rheumatic diseases are highlighted.
This is a preview of subscription content, log in via an institution to check access.
References
Norman, P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin. Investig. Drugs 23, 1067–1077 (2014).
Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020–1026 (2014).
McInnes, I. B. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780–789 (2013).
Stohl, W. & Hilbert, D. M. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat. Biotechnol. 30, 69–77 (2012).
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
Matucci-Cerinic, M. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 70, 32–38 (2011).
De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385–2395 (2012).
Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).
Sundy, J. S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. Two randomized controlled trials. JAMA 306, 711–720 (2011).
Baeten, D. et al. Anti-interleukin-17A monoclonal antibody secukinumabin treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382, 1705–1713 (2013).
Acknowledgements
Work in the author's laboratory is supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre, based at Newcastle Hospitals NHS Foundation Trust and Newcastle University, UK. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. The author is grateful to T. Aspray and P. Conaghan for their insights whilst preparing thismanuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has been a member of advisory boards for Celltrion, Hospira, Janssen, Novartis, Pfizer and Roche.
Rights and permissions
About this article
Cite this article
Isaacs, J. 10 years of therapeutic advances in the rheumatic diseases. Nat Rev Rheumatol 11, 628–630 (2015). https://doi.org/10.1038/nrrheum.2015.138
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.138
- Springer Nature Limited